Growth Hormone Deficiency Epidemiology Forecast

Key Highlights

• In 2024, the United States recorded the highest number of GHD cases among the 7MM, with approximately 88 thousand cases. This number is projected to grow to nearly 94 thousand by 2034, driven by a compound annual growth rate (CAGR) of 0.6%. The increase is largely attributed to enhanced diagnostic tools, rising awareness among healthcare professionals and caregivers, and improvements in early screening practices.
• Within the EU4 and the UK, Germany is expected to report the highest number of diagnosed prevalent cases of GHD, with the UK and France following closely behind.
• According to DelveInsight’s analysis, GHD is more prevalent among males compared to females across the 7MM in 2024. Moreover, prevalent cases are projected to rise by 2034, reflecting a growing recognition and diagnosis of the condition across both genders.
• In Japan, an estimated 24 thousand cases of GHD were attributed to idiopathic etiology in 2024, while approximately 2,600 cases were linked to organic causes. This distribution underscores the predominance of idiopathic cases in the overall GHD burden, highlighting the need for continued research into underlying mechanisms and tailored diagnostic approaches.
• DelveInsight analysts note that the rising prevalence of GHD is influenced by factors such as population growth especially within the pediatric population and improved access to specialized healthcare services.

DelveInsight’s “Growth Hormone Deficiency Epidemiology Forecast – 2034” report delivers an in-depth understanding of GHD, historical and forecasted epidemiology of GHD in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Growth Hormone Deficiency (GHD) Understanding

Growth Hormone Deficiency (GHD) Overview

GHD is a rare condition resulting from insufficient production of growth hormone by the anterior pituitary gland, a small structure at the base of the brain responsible for regulating several hormonal functions. GHD may be congenital caused by genetic mutations or brain malformations or acquired later in life due to factors such as head trauma, infections, radiation exposure, or tumors. In some cases, no clear cause is identified, and the condition is classified as idiopathic. In children, GHD symptoms include delayed development of facial bones and teeth, slow growth of long bones, fine hair, underdeveloped nails, central obesity, a high-pitched voice, and delayed closure of skull sutures. In adults, the condition typically presents as increased abdominal fat, decreased muscle mass, fatigue, emotional disturbances like anxiety and depression, and unfavorable lipid levels, including elevated LDL cholesterol and triglycerides.

Growth Hormone Deficiency (GHD) Diagnosis

A precise biochemical diagnosis is crucial for confirming acquired adult GHD, as patients with this condition typically do not exhibit the short stature commonly seen in children. The symptoms, while common, are often nonspecific, and Growth Hormone (GH) replacement therapy is approved only for individuals with a confirmed deficiency. Given that GH secretion occurs in pulses, a single random serum measurement is not adequate for diagnosis. Instead, accurate evaluation requires assessing the secretory reserve through validated provocative tests, each of which has its own strengths and limitations. This approach is recommended for patients suspected of pituitary deficiency—particularly those with central obesity, reduced muscle mass, and hyperlipidemia—and is also important for retesting the GH axis in adults who were treated with GH during childhood to promote linear growth.

Further details related to diagnosis are provided in the report…

Growth Hormone Deficiency (GHD) Epidemiology

For the purpose of designing the patient-based model for GHD, the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of GHD, total diagnosed prevalent cases of GHD, total diagnosed prevalent cases of pediatric GHD, total diagnosed prevalent cases of adult GHD,  gender-specific cases of GHD and etiology-specific cases of GHD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2021 to 2034.

• DelveInsight analysts estimate that in 2024, there were approximately 207 thousand prevalent cases of GHD across the 7MM.
• In 2024, the United States accounted for approximately 71 thousand diagnosed prevalent cases of GHD, representing around 43% of the total cases across the 7MM, reflecting its significant share in the overall disease burden.
• In 2024, GHD was observed to be more prevalent among adults than pediatric patients across the EU4 and the UK. Approximately 56 thousand cases were reported in adults, compared to nearly 12 thousand cases in the paediatric population, highlighting the higher disease burden in the adult demographic.
• According to DelveInsight’s analysis, in Germany in 2024, males accounted for approximately 60% of GHD cases, while females represented around 40%. This gender distribution suggests a higher diagnostic prevalence or susceptibility among the male population.
• DelveInsight experts report that in the UK in 2024, idiopathic GHD accounted for more than 14 thousand cases, significantly outnumbering the 1,600 cases attributed to organic etiology. This disparity highlights the predominance of idiopathic causes in the GHD landscape.
• In 2024, Japan reported approximately 26 thousand diagnosed prevalent cases of GHD, accounting for around 17% of the country's total diagnosed GHD cases. Moreover, this number is projected to increase, reaching nearly 27 thousand cases by 2034.
• In Japan, an estimated 17 thousand male cases of GHD were reported in 2024, with projections indicating a continued increase in the coming years. This rising trend underscores the expanding burden of GHD and highlights the need for effective therapeutic strategies to address its multifaceted symptoms within the Japanese population.
• Growth Hormone Deficiency (GHD) Cases in the EU4 and the UK

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the UW Health American Family Children's Hospital, US; Children's Hospital Los Angeles, US; University Hospital Heidelberg, Germany; Policlinico Sant'Orsola-Malpighi, Italy; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Spain; University of Manchester, the UK; Tanaka Growth Clinic, Japan and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Growth Hormone Deficiency Epidemiology Report

• The report covers a segment of executive summary, descriptive overview of GHD explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Growth Hormone Deficiency (GHD) Report Insights

• Growth Hormone Deficiency Patient Population
• Country-wise Epidemiology Distribution
• Total Prevalent Cases of GHD
• Total Diagnosed Prevalent Cases of GHD
• Total Diagnosed Prevalent Cases of Pediatric GHD
• Total Diagnosed Prevalent Cases of Adult GHD
• Gender-specific Cases of GHD
• Etiology-specific Cases of GHD

Growth Hormone Deficiency (GHD) Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Growth Hormone Deficiency (GHD) Epidemiology Segmentation

Growth Hormone Deficiency (GHD) Report Assessment

• Current Diagnostic Practices
• Growth Hormone Deficiency Patient Segmentation
•  

Growth Hormone Deficiency Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of GHD? What will be the growth opportunities across the 7MM concerning the patient population of GHD?
• What is the historical and forecasted GHD patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of GHD in Japan lower than the US?
• Which country has a high patient share for GHD?

Reasons to Buy Growth Hormone Deficiency Epidemiology Report

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the GHD prevalence cases in varying geographies over the coming years.
• A detailed overview of diagnosed prevalence of GHD, along with diagnosed prevalence of GHD based on type and diagnosed prevalence of GHD based on gender and etiology.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1.           What is the forecast period covered in the report?

The GHD Epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2.           Out of all EU4 countries and the UK, which country had the highest population of GHD cases in 2024?

The highest cases of GHD was found in the Germany among EU4 and the UK in 2024.

3.           How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4.           Out of all 7MM countries, which country had the highest population of GHD cases in 2024?

The highest cases of GHD were found in the US among the 7MM in 2024.